Enzymotec Ltd. announced that its Board of Directors has appointed Erez Israeli as President and Chief Executive Officer effective April 18, 2017. Mr. Israeli succeeds Dr. Ariel Katz, who has served as Enzymotec's President and Chief Executive Officer since 2001. Mr. Israeli was most recently the President and CEO of Growth Markets at Teva Pharmaceuticals where he oversaw all commercial activities in Asia, Asia Pacific, Africa and Latin America.

Since joining Teva in 1994, he has held various leadership roles including the Head of Global Quality, President and CEO of Teva API and President, and Group Executive Vice President and Chief Business Process Officer at Teva.